Clinical Trial Update: BGJ398 for Patients With Tumors With FGFR Genetic Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial update of BGJ398 (infigratinib) for tumors with FGFR genetic alterations; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumor

Drugs mentioned

• BGJ398 (BGJ398)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Solid Tumor, Hematologic Malignancies | Phase 2 | Status: TERMINATED | Results posted: 2019-06-18